Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1264484
1. Krishna MB, Joseph A, Thomas PL, Dsilva B, Pillai SM, Laloraya M: Impaired Arginine Metabolism Coupled to a Defective Redox Conduit Contributes to Low Plasma Nitric Oxide in Polycystic Ovary Syndrome. Cell Physiol Biochem; 2017 Oct 20;43(5):1880-1892

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired Arginine Metabolism Coupled to a Defective Redox Conduit Contributes to Low Plasma Nitric Oxide in Polycystic Ovary Syndrome.
  • BACKGROUND: Though oxidative stress is associated with Polycystic Ovary Syndrome (PCOS), the status of nitric oxide is still unclear.
  • Nitric Oxide (NO) plays pivotal roles in many physiological functions which are compromised in PCOS.
  • We analysed NOx (nitrite+nitrate) and hydrogen peroxide (H2O2) concentrations, transcript levels of endothelial nitric oxide synthase (eNOS)/inducible nitric oxide synthase (iNOS) and arginine modulators, hydrogen peroxide regulators in the cohort.
  • RESULTS: PCOS women showed reduced plasma NOx(nitrate+nitrite) and H2O2 compared to controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Author(s). Published by S. Karger AG, Basel.
  • (PMID = 29055959.001).
  • [ISSN] 1421-9778
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Arginine bioavailability / Hydrogen peroxide / Nitric Oxide Synthase / Nitric oxide / Polycystic ovarian syndrome
  •  go-up   go-down


2. Butov DO, Kuzhko M, Butova T, Stepanenko G: Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without multidrug-resistant tuberculosis undergoing the intensive phase of antituberculosis therapy. Int J Mycobacteriol; 2016 Dec;5 Suppl 1:S154-S155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without multidrug-resistant tuberculosis undergoing the intensive phase of antituberculosis therapy.
  • OBJECTIVE/BACKGROUND: There is a paucity of published data on the effect of tuberculosis (TB) chemotherapy on nitric oxide (NO) synthesis and metabolism in newly diagnosed and relapsed patients with or without multidrug-resistant TB (MDR-TB).
  • METHODS: The pattern of NO response in 140 patients with pulmonary TB, including 74 with MDR-TB (1st group) and 66 without MDR-TB (2nd group) has been studied and compared with the NO status of 30 healthy donors (3rd group).
  • Patients comprised those with newly diagnosed pulmonary TB (Subgroups 1B and 2B) and recurrent or relapsed TB (Subgroups 1A and 2A).
  • CONCLUSION: In patients with pulmonary TB, significantly higher levels of NO activity were observed as compared with the levels in healthy individuals.
  • In patients with recurrent TB and MDR-TB, significantly lower levels of NO indicators were observed in comparison with patients with newly diagnosed pulmonary TB.
  • After 2months on chemotherapy, a significant decrease in iNOS activity and NO metabolites was observed in patients with pulmonary TB, but the decrease in NO indicators was manifested mostly in the newly diagnosed pulmonary TB patients and patients without MDR-TB as opposed to patients with recurrent TB and MDR-TB, which suggests lower levels of immunologic and reparative processes in such patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016.
  • (PMID = 28043522.001).
  • [ISSN] 2212-554X
  • [Journal-full-title] International journal of mycobacteriology
  • [ISO-abbreviation] Int J Mycobacteriol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Inducible nitric oxide synthase / Multidrug-resistant tuberculosis / Nitrates / Nitric oxide / Nitrites / Tuberculosis
  •  go-up   go-down


3. Le DQ, Kuriakose AE, Nguyen DX, Nguyen KT, Acharya S: Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases. Sci Rep; 2017 Aug 18;7(1):8692

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases.
  • Nitric oxide (NO) has been known to promote physiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vascular endothelial growth factor (VEGF) level in endothelial cells (ECs) and preventing platelet adherence and leukocyte chemotaxis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Pharmacol. 1989;14 Suppl 11:S13-22 [2484692.001]
  • [Cites] J Biomed Mater Res A. 2012 Aug;100(8):1998-2005 [22566409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13683-8 [15347817.001]
  • [Cites] Nanomedicine. 2010 Apr;6(2):355-61 [19699325.001]
  • [Cites] Nutrients. 2013 Jul 31;5(8):2969-3004 [23912327.001]
  • [Cites] J Ethnopharmacol. 2012 May 7;141(1):250-6 [22366433.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11317-24 [8626684.001]
  • [Cites] Vasc Med. 1997;2(3):252-6 [9546976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9161-6 [22570497.001]
  • [Cites] J Diabetes Complications. 2012 Mar-Apr;26(2):137-40 [22464549.001]
  • [Cites] Eur Heart J. 2001 Jun;22(11):903-18 [11428814.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1232-40 [15841216.001]
  • [Cites] Cardiovasc Surg. 1998 Aug;6(4):367-72 [9725515.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Jul;28(1):9-23 [15177227.001]
  • [Cites] Wound Repair Regen. 2013 Jul-Aug;21(4):545-53 [23627689.001]
  • [Cites] Circulation. 2014 Jan 21;129(3):e28-e292 [24352519.001]
  • [Cites] Cardiol Res Pract. 2012;2012:656247 [22536531.001]
  • [Cites] Acta Biomater. 2012 Aug;8(8):2996-3004 [22561668.001]
  • [Cites] Korean J Hepatol. 2011 Dec;17(4):251-7 [22310788.001]
  • [Cites] PLoS One. 2014 Oct 03;9(10):e109017 [25280018.001]
  • [Cites] J Cereb Blood Flow Metab. 2012 May;32(5):825-34 [22186670.001]
  • [Cites] Gene. 2013 Aug 10;525(2):220-8 [23566831.001]
  • [Cites] Nitric Oxide. 2013 Nov 30;35:175-85 [24095696.001]
  • [Cites] J Biomed Mater Res A. 2015 May;103(5):1632-9 [25088162.001]
  • [Cites] Nitric Oxide. 2009 Jun;20(4):231-7 [19371597.001]
  • [Cites] Free Radic Res. 2015 Feb;49(2):122-32 [25373783.001]
  • [Cites] J Nanosci Nanotechnol. 2012 Jan;12(1):236-44 [22523971.001]
  • [Cites] Front Biosci (Landmark Ed). 2011 Jan 01;16:1873-97 [21196271.001]
  • [Cites] Int J Mol Sci. 2014 Jun 25;15(7):11324-49 [24968272.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2894-903 [17720765.001]
  • [Cites] Yonsei Med J. 2016 Nov;57(6):1329-38 [27593859.001]
  • [Cites] J Pharm Pharm Sci. 2015;18(5):696-704 [26670366.001]
  • [Cites] Acta Biomater. 2014 Jun;10(6):2643-52 [24512977.001]
  • [Cites] Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d [21890489.001]
  • [Cites] Xenotransplantation. 2015 Sep-Oct;22(5):391-8 [26381495.001]
  • [Cites] PLoS One. 2016 Jul 08;11(7):e0158672 [27391949.001]
  • [Cites] Mymensingh Med J. 2009 Jul;18(2):264-72 [19623159.001]
  • [Cites] Int J Pharm. 2016 Sep 25;511(2):1022-32 [27521705.001]
  • [Cites] Br J Pharmacol. 2014 May;171(9):2321-34 [24405159.001]
  • [Cites] Bioorg Med Chem Lett. 2016 Mar 1;26(5):1490-4 [26832784.001]
  • [Cites] J Am Coll Cardiol. 2008 Jul 22;52(4):251-4 [18634978.001]
  • [Cites] J Am Coll Cardiol. 2011 Jan 4;57(1):93-8 [21185507.001]
  • [Cites] Int J Inflam. 2014;2014:689360 [24804145.001]
  • [Cites] Circ Res. 2002 Jan 11;90(1):21-8 [11786514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8306-11 [12048254.001]
  • [Cites] Free Radic Biol Med. 2015 Dec;89:1165-75 [26546694.001]
  • [Cites] Nitric Oxide. 2012 May 15;26(4):217-22 [22426034.001]
  • [Cites] Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:595-600 [26478349.001]
  • [Cites] J Biomed Opt. 2012 Apr;17(4):046003 [22559681.001]
  • [Cites] J Nanosci Nanotechnol. 2011 Apr;11(4):3533-42 [21776734.001]
  • (PMID = 28821752.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL118498
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Miragem AA, Homem de Bittencourt PI Jr: Nitric oxide-heat shock protein axis in menopausal hot flushes: neglected metabolic issues of chronic inflammatory diseases associated with deranged heat shock response. Hum Reprod Update; 2017 Sep 01;23(5):600-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide-heat shock protein axis in menopausal hot flushes: neglected metabolic issues of chronic inflammatory diseases associated with deranged heat shock response.
  • OBJECTIVE AND RATIONALE: This review focuses on HSP70 and its accompanying heat shock response (HSR), which is an anti-inflammatory and antisenescent pathway whose intracellular triggering is also oestrogen-dependent via nitric oxide (NO) production.
  • OUTCOMES: Oestrogen elicits rapid production of the vasodilatory gas NO, a powerful activator of HSP70 expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28903474.001).
  • [ISSN] 1460-2369
  • [Journal-full-title] Human reproduction update
  • [ISO-abbreviation] Hum. Reprod. Update
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; cardiovascular disease / cellular senescence / chronic inflammatory diseases / heat shock response / heat therapy / hot flushes / insulin resistance / menopause / obesity / thermoregulation
  •  go-up   go-down


5. Al-Ali MK, Howarth PH: Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia. Saudi Med J; 2001 Mar;22(3):249-53
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia.
  • OBJECTIVE: Nitric oxide is known to be present in the exhaled air of normal subjects and at higher concentrations in asthmatics.
  • The aim of this study was to measure exhaled nitric oxide levels in patients admitted to hospital with acute exacerbations of asthma, or chronic obstructive pulmonary disease, or with pneumonia.
  • METHODS: Within 24 hours of admission exhaled nitric oxide levels were measured by a chemiluminescent analyzer in 11 patients with acute sever asthma, 19 patients with acute exacerbation of chronic obstructive pulmonary disease, and in 12 patients with pneumonia.
  • RESULTS: On admission median exhaled nitric oxide levels (range) were significantly higher in asthmatics 22 (9.3-74) parts per billion in comparison to patients with chronic obstructive pulmonary disease 10.3 (2.7-34) parts per billion; p < 0.01, pneumonia 7 (4-17) parts per billion; p<0.001, and normal subjects 8.7 (5-13.3) parts per billion; p < 0.001.
  • Following treatment the asthmatics had a significant reduction in their exhaled nitric oxide levels from 22 (9.3-74) parts per billion on day 1 to 9.7 (5.7-18.3) parts per billion on day 28; p = 0.005.
  • A strong negative correlation existed between peak expiratory flow rate measurements and exhaled nitric oxide levels in asthmatics on day 28 (r = -0.70; p = 0.017).
  • CONCLUSION: Acute exacerbations of asthma are associated with increased levels of exhaled nitric oxide in contrast to exacerbations of chronic obstructive pulmonary disease and acute pneumonia.
  • Exhaled nitric oxide may be a useful indirect marker of asthmatic airway inflammation.
  • The differing time course of response of nitric oxide to peak flow measures suggests that these two measures are reflecting differing airway events.
  • [MeSH-major] Asthma / metabolism. Breath Tests. Lung Diseases, Obstructive / metabolism. Nitric Oxide / analysis. Pneumonia / metabolism


6. Zeng WP, Zhang R, Li R, Luo JF, Hu XF: Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent. PLoS One; 2017;12(1):e0170964
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.
  • Genotyping was performed on six single nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase gene (eNOS), the angiotensin converting enzyme gene (ACE), the angiotensin II type 1 receptor gene (AT1R), the transforming growth factor beta gene (TGF-β), and the vascular endothelial growth factor gene (VEGF).
  • Of the six analyzed SNPs, the frequency of the C allele of T786C polymorphism in eNOS was significantly higher in the ISR group (22.2%) compared to the non-ISR group (12.7%) (p<0.01).
  • In the ISR group, the frequency of the TT, TC, and CC genotypes was 61.1%, 33.3%, and 5.6%, respectively, and in the non-ISR group, the frequencies were 76.8%, 21.0%, and 2.2%, respectively.
  • [MeSH-major] Coronary Artery Disease / genetics. Coronary Restenosis / genetics. Drug-Eluting Stents / adverse effects. Nitric Oxide Synthase / genetics

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 1999 Jun 8;99(22):2864-70 [10359729.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1769-76 [12426203.001]
  • [Cites] N Engl J Med. 1995 Mar 16;332(11):706-11 [7854377.001]
  • [Cites] Hum Mol Genet. 2000 Nov 1;9(18):2629-37 [11063722.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1955-62 [12473258.001]
  • [Cites] Histochem Cell Biol. 2001 Dec;116(6):471-81 [11810189.001]
  • [Cites] J Am Coll Cardiol. 2002 Dec 18;40(12):2072-81 [12505216.001]
  • [Cites] Circulation. 1997 Jul 1;96(1):56-60 [9236417.001]
  • [Cites] Int J Clin Exp Pathol. 2015 Jun 01;8(6):7350-7 [26261635.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):496-501 [8041414.001]
  • [Cites] JAMA. 2007 Jan 10;297(2):159-68 [17148711.001]
  • [Cites] PLoS One. 2012;7(5):e37878 [22662243.001]
  • [Cites] Clin Chim Acta. 2006 Mar;365(1-2):86-92 [16157324.001]
  • [Cites] Heart. 2014 Jan;100(2):153-9 [24270744.001]
  • [Cites] J Am Coll Cardiol. 2006 Jul 4;48(1):193-202 [16814667.001]
  • [Cites] Cardiovasc Res. 2008 Jan;77(1):19-29 [17658499.001]
  • [Cites] Circulation. 2004 Feb 10;109(5):634-40 [14769686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2832-5 [10717002.001]
  • [Cites] J Card Fail. 2010 Apr;16(4):314-9 [20350698.001]
  • [Cites] PLoS One. 2014 Nov 19;9(11):e113363 [25409023.001]
  • [Cites] Angiology. 2015 Aug;66(7):652-8 [25155040.001]
  • [Cites] Am J Cardiol. 2000 Sep 15;86(6):628-34 [10980213.001]
  • [Cites] Hum Mol Genet. 2002 Feb 1;11(3):229-41 [11823442.001]
  • [Cites] Int J Cardiol. 2002 Nov;86(1):71-6 [12243851.001]
  • [Cites] J Am Coll Cardiol. 2011 Mar 15;57(11):1314-22 [21376502.001]
  • [Cites] Medicine (Baltimore). 2016 May;95(19):e3413 [27175642.001]
  • [Cites] Exp Mol Pathol. 2015 Feb;98(1):13-7 [25449332.001]
  • [Cites] Pharmacogenet Genomics. 2006 May;16(5):331-7 [16609364.001]
  • [Cites] PLoS One. 2016 Mar 01;11(3):e0150500 [26930482.001]
  • [Cites] Thromb Res. 2007;119(5):579-85 [16842840.001]
  • [Cites] Eur Heart J. 2013 Nov;34(42):3304-13 [23824827.001]
  • [Cites] N Engl J Med. 2009 May 7;360(19):1933-45 [19420363.001]
  • [Cites] Circulation. 1998 Jan 20;97(2):147-54 [9445166.001]
  • [Cites] Clin Sci (Lond). 2007 Jul;113(2):47-63 [17555404.001]
  • [Cites] Atherosclerosis. 2007 Aug;193(2):438-44 [16938300.001]
  • [Cites] J Vasc Res. 2010;47(4):309-22 [20016205.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 May;26(5):1114-9 [16543493.001]
  • [Cites] Mol Cell Biochem. 2012 Nov;370(1-2):241-9 [22890915.001]
  • [Cites] Curr Opin Pharmacol. 2013 Apr;13(2):161-7 [23395155.001]
  • [Cites] J Pathol. 2000 Feb;190(3):244-54 [10685059.001]
  • [Cites] J Am Coll Cardiol. 2001 Nov 1;38(5):1434-9 [11691520.001]
  • [Cites] EuroIntervention. 2014 Jun;10 (2):224-30 [24168783.001]
  • [Cites] Pharmacology. 2010;85(4):211-6 [20215811.001]
  • (PMID = 28129392.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


7. Maccallini C, Amoroso R: Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders. Neural Regen Res; 2016 Nov;11(11):1731-1734

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders.
  • In this short review we analyze some promising advancements in the search of new bioactive molecules targeting neuronal nitric oxide synthase (nNOS), an enzyme deputed to the biosynthesis of nitric oxide (NO).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Pharmacol. 2013 Aug;169(7):1417-29 [23617570.001]
  • [Cites] Nat Med. 2010 Dec;16(12 ):1439-43 [21102461.001]
  • [Cites] ChemMedChem. 2016 Aug 19;11(16):1695-9 [27377568.001]
  • [Cites] J Med Chem. 2012 Jan 26;55(2):943-55 [22175766.001]
  • [Cites] Clin Ther. 2010 Jan;32(1):146-60 [20171420.001]
  • [Cites] J Neurosci. 1999 Dec 1;19(23):10250-61 [10575022.001]
  • [Cites] Science. 2002 Oct 25;298(5594):846-50 [12399596.001]
  • [Cites] Springerplus. 2016 May 17;5:637 [27330903.001]
  • [Cites] Mini Rev Med Chem. 2013 Jul;13(9):1305-10 [23621655.001]
  • [Cites] Bioorg Med Chem Lett. 2012 Mar 1;22(5):1980-4 [22318159.001]
  • [Cites] Front Cell Neurosci. 2015 Aug 17;9:322 [26347610.001]
  • [Cites] Brain Res Bull. 2016 Jul;125:99-105 [27237129.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):117-26 [15631993.001]
  • [Cites] Br J Pharmacol. 2013 Mar;168(5):1255-65 [23072468.001]
  • [Cites] J Med Chem. 2015 Feb 12;58(3):1064-6 [25602734.001]
  • (PMID = 28123402.001).
  • [ISSN] 1673-5374
  • [Journal-full-title] Neural regeneration research
  • [ISO-abbreviation] Neural Regen Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Keywords] NOTNLM ; NMDAR / PSD95 / amidines / carbonic anhydrase / inhibitors / neurological diseases / neuronal nitric oxide synthase
  •  go-up   go-down


8. Zhang HQ, Zhang HQ, Zhang JJ, Liu YD, Deng YL, Luo JF, Niu HH, Sun X: [Application of pulmonary function and fractional exhaled nitric oxide tests in the standardized management of bronchial asthma in children]. Zhongguo Dang Dai Er Ke Za Zhi; 2017 Apr;19(4):419-424
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of pulmonary function and fractional exhaled nitric oxide tests in the standardized management of bronchial asthma in children].
  • OBJECTIVE: To investigate the changes of pulmonary function and fractional exhaled nitric oxide (FeNO) in the standardized treatment of bronchial asthma in children.
  • The pulmonary function parameters included forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), maximal mid-expiratory flow (MMEF), and mid-expiratory flow at 25%, 50%, and 75% of vital capacity (MEF25, MEF50, and MEF75).
  • Another 62 healthy children were selected as the control group, and the pulmonary function and FeNO levels were measured only once.
  • Before treatment, there was a significant negative correlation between FeNO levels and pulmonary function parameters (P<0.05).
  • CONCLUSIONS: With the standardized treatment of bronchial asthma in children, pulmonary function parameters gradually increase and FeNO levels gradually decrease.
  • [MeSH-major] Asthma / therapy. Breath Tests. Lung / physiopathology. Nitric Oxide / analysis

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28407829.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


9. Buie JJ, Renaud LL, Muise-Helmericks R, Oates JC: IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. J Immunol; 2017 Sep 15;199(6):1979-1988
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus.
  • Systemic lupus erythematosus (SLE) is a known risk factor for endothelial dysfunction.
  • However, the impact of IFN-α on mediators that induce vasodilation and modulate inflammation, including endothelial NO synthase (eNOS) and NO bioavailability, are unknown.
  • The objectives of this study were to determine how IFN-α promotes endothelial dysfunction in SLE, focusing on its regulation of eNOS and NO production in endothelial cells.
  • We demonstrate that IFN-α promotes an endothelial dysfunction signature in HUVECs that is characterized by transcription suppression and mRNA instability of eNOS complemented by upregulation of MCP1 and <i>VCAM1</i> These changes are associated with IFN-inducible gene expression.
  • IFN-α treatment also led to enhanced neutrophil adhesion.
  • This could promote the development of endothelial dysfunction and cardiovascular disease in SLE.
  • [MeSH-major] Blood Vessels / pathology. Endothelium, Vascular / pathology. Interferon-alpha / metabolism. Lupus Erythematosus, Systemic / immunology. Neutrophils / immunology. Nitric Oxide / metabolism. Nitric Oxide Synthase / metabolism
  • [MeSH-minor] Animals. Autoantigens / genetics. Autoantigens / metabolism. Cell Adhesion. Gene Expression Regulation. Human Umbilical Vein Endothelial Cells. Humans. Insulin / immunology. Mice. MicroRNAs / genetics. Vascular Cell Adhesion Molecule-1 / genetics. Vascular Cell Adhesion Molecule-1 / metabolism

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 by The American Association of Immunologists, Inc.
  • [Cites] J Immunol. 2004 Feb 1;172(3):1699-710 [14734752.001]
  • [Cites] Cardiovasc Res. 2014 Jul 1;103(1):5-6 [24907979.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):766-8 [15220374.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 21;361(2):462-7 [17651694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5 [12604793.001]
  • [Cites] Diabetes Metab Res Rev. 2007 Oct;23(7):559-66 [17385193.001]
  • [Cites] Rheumatology (Oxford). 2015 Jun;54(6):1114-23 [25416712.001]
  • [Cites] Cardiovasc Res. 2005 Mar 1;65(4):768-9 [15721855.001]
  • [Cites] Arthritis Res Ther. 2011 Feb 28;13(1):203 [21371346.001]
  • [Cites] J Immunol. 2010 Oct 1;185(7):4457-69 [20805419.001]
  • [Cites] Ann Acad Med Stetin. 2008;54(2):22-32 [19374227.001]
  • [Cites] J Interferon Cytokine Res. 2014 May;34(5):404-12 [24444308.001]
  • [Cites] Hypertension. 2012 Dec;60(6):1407-14 [23108656.001]
  • [Cites] Am J Med. 1976 Feb;60(2):221-5 [1251849.001]
  • [Cites] Circulation. 2000 Apr 4;101(13):1539-45 [10747347.001]
  • [Cites] Arthritis Rheum. 2006 Jun;54(6):1906-16 [16736505.001]
  • [Cites] J Rheumatol. 1995 Jul;22(7):1265-70 [7562756.001]
  • [Cites] Cell Cycle. 2010 Jan 1;9(1):131-9 [20016288.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2907-15 [17638846.001]
  • [Cites] PLoS One. 2012;7(5):e37000 [22606325.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1237-47 [18438839.001]
  • [Cites] Clin Exp Rheumatol. 1994 Nov-Dec;12(6):689-90 [7895410.001]
  • [Cites] Am J Epidemiol. 1997 Mar 1;145(5):408-15 [9048514.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6306-13 [10570325.001]
  • [Cites] Diabetes. 2007 Mar;56(3):666-74 [17327434.001]
  • [Cites] J Immunol. 2010 Nov 15;185(10 ):6226-33 [20937844.001]
  • [Cites] Transl Res. 2009 Aug;154(2):61-9 [19595437.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3759-69 [17968925.001]
  • [Cites] Science. 1992 Apr 10;256(5054):225-8 [1373522.001]
  • [Cites] Gene. 2012 Apr 1;496(2):128-35 [22301267.001]
  • [Cites] Annu Rev Med. 2013;64:249-63 [23020882.001]
  • [Cites] Rheum Dis Clin North Am. 2010 Feb;36(1):173-86, x [20202598.001]
  • [Cites] PLoS One. 2013 May 31;8(5):e64650 [23741359.001]
  • [Cites] Biochem Biophys Res Commun. 2015 Aug 21;464(2):574-9 [26159918.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R736-42 [16971374.001]
  • [Cites] J Am Soc Hypertens. 2010 May-Jun;4(3):102-15 [20470995.001]
  • [Cites] Lipids Health Dis. 2015 Feb 18;14:9 [25888960.001]
  • [Cites] Cell Immunol. 2012 Mar-Apr;276(1-2):42-51 [22560558.001]
  • [Cites] Hypertension. 2014 Aug;64(2):330-7 [24842914.001]
  • [Cites] Arthritis Rheum. 2012 Sep;64(9):2975-85 [22549550.001]
  • [Cites] Hypertension. 2012 Dec;60(6):1381-2 [23108652.001]
  • (PMID = 28779021.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / F31 AR064150; United States / CSRD VA / CX / I01 CX001248; United States / NIAMS NIH HHS / AR / R01 AR045476; United States / NCATS NIH HHS / TR / UL1 TR000062; United States / NIGMS NIH HHS / GM / R25 GM072643; United States / NIAMS NIH HHS / AR / P60 AR062755
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Insulin; 0 / Interferon-alpha; 0 / MIRN155 microRNA, human; 0 / MicroRNAs; 0 / Vascular Cell Adhesion Molecule-1; 0 / metaphase chromosome protein 1, human; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


10. Maher A, Abdel Rahman MF, Gad MZ: The Role of Nitric Oxide from Neurological Disease to Cancer. Adv Exp Med Biol; 2017;1007:71-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Role of Nitric Oxide from Neurological Disease to Cancer.
  • Until the beginning of the 1980s, nitric oxide (NO) was just a toxic molecule of a lengthy list of environmental pollutants such as cigarette smoke and smog.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28840553.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; CNS / Cancer / NO signal transduction / NO-targeted therapy / NOS expression / Neurodegeneration disorders / Nitric oxide (NO)
  •  go-up   go-down






Advertisement